Cosmos Health has introduced its premium 18 Series nutraceutical platform in the United States, debuting three products—Noor18™, Liv18™, and Cur18™—designed to meet rigorous scientific standards. The move positions the company in three of the fastest-growing health supplement categories with a long-term goal of launching 18 clinically validated formulas.

Each 18 Series product must satisfy three core criteria: a patented active ingredient, at least one peer-reviewed randomized controlled trial, and delivery of the exact dose used in clinical research. This certification model creates a quality threshold few competitors can match, ensuring supply exclusivity and substantiated health claims.

Noor18™ targets the $1.6 billion US collagen market with a marine collagen tripeptide shown to reduce wrinkles by 25% in 12 weeks; Liv18™ enters the $4.6 billion liver health segment with a botanical blend proven to cut liver fat by 15% in over-50s; Cur18™ leverages enhanced-bioavailability curcumin for inflammation and joint support. Together these address a combined $7.8 billion opportunity.

The 18 Series is structured to generate compounding brand equity: each successful product bolsters the credibility of existing offerings, enhancing overall portfolio value. Cosmos Health aims to expand to 18 products across key biological systems, reinforcing its science-first mission and driving long-term growth.